Bafna Pharma Q3 FY26: PAT nearly triples YTD, auditor flags GST demands

Emphasis of matterProfit growth above 25%Results View source PDF Explain this filing

BAFNAPH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.6%Reaction day

₹130.00

prior close

₹126.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-5.1% vs market

On the reaction day the stock moved 5.1 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.7

10m

-1.7

15m

-1.4

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-5.6-0.5-5.1

Next day

-7.6-2.0-5.7

-8.3-2.7-5.6

-9.1-1.7-7.4

-10.7-1.4-9.3

-10.8-2.8-8.0

-14.2-2.8-11.4

15d

-12.5-8.4-4.1

-20.8-9.1-11.7

+3.1-4.0+7.1

+2.3+2.6-0.3

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bafna Pharmaceuticals posted Q3 FY26 revenue of about 3,829 lakhs, up 15% YoY. Nine-month revenue rose 1.5% to 10,838 lakhs. Nine-month PAT nearly tripled to 835 lakhs from 284 lakhs; Q3 PAT doubled to 184 lakhs from 95 lakhs. Auditor flagged emphasis of matter items: GST demands of 566 lakhs under appeal, pending forex receivables of 205 lakhs, and tax refund adjustment of 45 lakhs.

Likely market impact

Profit surge aided by higher revenue and absence of exceptional items vs prior year. GST demands and pending forex receivables are key risks to monitor.